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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Libyan Arabic 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data, and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 100 JIA patients (22.0% systemic, 26.0% oligoarticular, 25.0% RF nega-
tive polyarthritis, and 27.0% other categories) and 100 healthy children, were enrolled in a paediatric rheumatology centre. 
The JAMAR components discriminated well healthy subjects from JIA patients. Notably, there is no significant difference 
between the healthy subjects and their affected peers in the school-related problems variable. All JAMAR components 
revealed satisfactory psychometric performances. In conclusion, the Libyan Arabic version of the JAMAR is a valid tool for 
the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Libyan Arabic parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Libyan Arabic language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from March 2014 to 
December 2015. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored: 0 = without difficulty, 1 = with some diffi-
culty, 2 = with much difficulty, 3 = unable to do and not 
applicable if it was not possible to answer the question 
or the patient was unable to perform the task due to 
their young age or to reasons other than JIA. The total 
PF score ranges from 0 to 45 and has 3 components: 
PF-lower limbs (PF-LL); PF-hand and wrist (PF-HW) 
and PF-upper segment (PF-US) each scoring from 0 
to 15 [7]. Higher scores indicating higher degree of 
disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. The Libyan 
Arabic version is the result of the local adaptation of the 
translation in Arabic performed by the PRINTO centre in 
Saudi Arabia. Reading, comprehension, and understanding 
of the translated questionnaires were tested in a probe sam-
ple of 10 JIA parents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set of variables, with the addition 
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of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with the first 
and third quartiles and categorical data as absolute frequen-
cies and percentages.
The complete Libyan Arabic parent and patient versions 
of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Libyan Arabic JAMAR was fully cross-culturally 
adapted from the Arabic version performed by the PRINTO 
centre in Saudi Arabia with no forward and backward 
translation.
Of the 123 lines in the parent version of the JAMAR, 
121 (98.4%) were understood by at least 80% of the 10 
parents tested (median = 100%; range: 70–100%); 115/120 
(95.8%) lines of the patient version of the JAMAR were 
understood by at least 80% of the children (median = 100%; 
range: 70–100%). Lines 33 and 68 of the parent version of 
the JAMAR and lines 31, 32 53, 68, and 110 of the child 
version of the JAMAR were modified according to parents’ 
and patients’ suggestions, respectively.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total 
of 200 subjects) were enrolled at the paediatric rheumatol-
ogy centre of the Tripoli Children’s Hospital.
In the JIA subjects, the JIA categories were 22.0% with 
systemic arthritis, 26.0% with oligoarthritis, 25.0% with 
RF negative polyarthritis, 5.0% with RF positive polyar-
thritis, 4.0% with psoriatic arthritis, 13.0% with enthesitis-
related arthritis, and 5.0% with undifferentiated arthritis 
(Table 1).
All the 200 enrolled subjects had the parent version of 
the JAMAR completed by a parent (100 from parents of 
JIA patients and 100 from parents of healthy children). 
The JAMAR was completed by 180/200 (75.0%) moth-
ers and 50/200 (25.0%) fathers. The child version of the 
JAMAR was completed by 120/142 (90.0%) children age 
6.1 or older. In addition, patients younger than 7 years old, 
capable to assess their personal condition and able to read 
and write, were asked to fill in the patient version of the 
questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the 
PF, the PhH, the PsH subscales, and total score of the 
HRQoL scales. The JAMAR components discriminated 
well between healthy subjects and JIA patients. Notably, 
there is no significant difference between the healthy sub-
jects and their affected peers in the school-related prob-
lems variable.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a Web-based system that did 
not allow skipping answers and input of null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the differ-
ent HRQoL items except for item 6, whereas a reduced 
number of response choices were used for all the PF items 
except for items 1, 3, 4, 5, 10, and 12.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 0% (0–1.0%) for the PF and 3.0% (2–5.0%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 88.0% (82.0–92.0%) for the PF 
items, 69.0% (69.0–70.0%) for the HRQoL PhH items, and 
67.0% (62.0–70.0%) for the HRQoL PsH items. The median 
ceiling effect was 0.0% (0.0–1.0%) for the PF items, 2.0% 
(1.0–2.0%) for the HRQoL PhH items, and 1.0% (1.0–2.0%) 
for the HRQoL PsH items. The median floor effect was 
50.0% for the pain VAS, 51.0% for the disease activity VAS, 
and 51.0% for the well-being VAS. The median ceiling effect 
was 2.0% for the pain VAS, 3.0% for the disease activity 
VAS, and 6.0% for the well-being VAS.
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies, and %) for the 200 JIA patients
Data related to the JAMAR refer to the 100 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF− Polyar-
thritis
RF + Polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 22 N = 26 N = 25 N = 5 N = 4 N = 13 N = 5 N = 100 N = 100
Female 12 (54.5%) 20 (76.9%) 23 (92%) 4 (80%) 2 (50%) 7 (53.8%) 2 (40%) 70 (70%) 56 (56%)*
Age at visit 11.8 
(8.7–13.1)
9.6 (5.3–13.2) 11.2 
(9.1–15.2)
16.2 (11.3–
16.3)
14.1 (11.5–
15.4)
12.9 (11.3–
14.7)
9.5 (8.2–13.1) 11.3 
(8.2–14.9)
12.3 (10-
14.3)
Age at onset 5.5 (2.8–9.2) 3.1 (1.8-8) 5.9 (3.7–9.6) 10.2 
(9.4–13.1)
12.8 (10.4–
13.7)
11 (7.3–11.6) 6.8 (6.5–11) 6.4 (3.1–
10.4)*
Disease duration 5.2 (3.3–7) 3.5 (2.5–6.9) 3.3 (1.2–9.6) 3.2 (2.4–3.8) 1.3 (0.8-2) 3.3 (1.6–4.1) 1.7 (1.4–2.1) 3.4 (1.7–
6.9)*
ESR 8 (5–11) 17 (14–25) 17 (11–28) 6 (5–10) 12.5 (8–17.5) 10 (6–20) 5 (4–10) 14 (7.5–
23.5)**
MD VAS 0 (0–2) 0 (0–1) 1.5 (0–3.5) 2 (0.5–4) 2.5 (1–4.3) 1.5 (0.5–4) 2 (0.5–2) 1 (0–2.5)*
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0)
No. joints with 
pain
0 (0–0) 0 (0–0) 0 (0–2) 0 (0–0) 8 (0–19) 1 (0–2) 0 (0–0) 0 (0–1)
No. joints with 
LOM
0 (0–1) 0 (0–0) 2 (0–6) 1 (1–3) 0 (0–13) 1 (0–4) 0 (0–2) 0 (0–3)*
No. active joints 0 (0–0) 0 (0–0) 0 (0–2) 0 (0–0) 0 (0–11) 1 (0–3) 0 (0–0) 0 (0–1)*
Active systemic 
features
2 (9.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2%)
ANA status 1 (4.5%) 6 (23.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 7 (7%)
Uveitis 0 (0%) 1/25 (4%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2/99 (2%)
PFt Score 0 (0–2) 0 (0–1) 3 (0–8) 6 (2–9) 5.5 (2–8) 3 (1–5) 1 (1–4) 1 (0–4)* 0 (0–0)#
Pain VAS 0 (0–1) 0 (0–0.5) 0 (0–2.5) 1 (0.5–1.5) 3 (2.3–5.5) 1.5 (0.5–4.5) 5 (4–5) 0.3 (0–3.3)* 0 (0–0)#
Disease Activity 
VAS
0.5 (0–2.5) 0 (0–2) 0 (0–3) 1.5 (0.5–1.5) 3.5 (1–5.3) 0.5 (0–5) 2 (1–5) 0 (0–3.3)
Well-being VAS 3 (0.5–5) 0 (0–1) 0 (0–2) 1.5 (0–1.5) 2.8 (0.5–5) 0.5 (0–4) 3 (0–5) 0 (0–4)*
HRQoL PhH 1 (0–1) 0 (0–2) 1 (0–5) 2 (1–5) 3 (1.5–3.5) 2 (1–4) 3 (3–3) 1 (0–3) 0 (0–0)#
HRQoL PsH 1 (0–4) 1 (0–3) 1 (0–4) 2 (1–6) 0 (0–0.5) 2 (0–3) 3 (1–5) 1 (0–4) 0 (0–0)#
HRQoL Total 
Score
2.5 (0–6) 1.5 (0–5) 3 (0–10) 3 (3–11) 3 (1.5–4) 4 (3–8) 6 (5–7) 3 (0-7.5) 0 (0–0)#
Pain/swell. in > 1 
joint
7 (31.8%) 10 (38.5%) 11 (44%) 4 (80%) 3 (75%) 9 (69.2%) 4 (80%) 48 (48%)* 3 (3%)#
Morning stiff-
ness > 15 min
2 (9.1%) 1 (3.8%) 3 (12%) 1 (20%) 1 (25%) 3 (23.1%) 1 (20%) 12 (12%) 0 (0%)**
Subjective remis-
sion
9 (40.9%) 7 (26.9%) 7 (28%) 3 (60%) 3 (75%) 7 (53.8%) 5 (100%) 41 (41%)*
In treatment 14 (63.6%) 16 (61.5%) 19 (76%) 4 (80%) 4 (100%) 9 (69.2%) 4 (80%) 70 (70%)
Reporting side 
effects
4/14 (28.6%) 3/16 (18.8%) 2/19 (10.5%) 1/4 (25%) 0 (0%) 3/9 (33.3%) 1/4 (25%) 14/70 (20%)
Taking medication 
regularly
13/14 (92.9%) 12/16 (75%) 17/19 (89.5%) 4/4 (100%) 4 (100%) 7/9 (77.8%) 4/4 (100%) 61/70 
(87.1%)
With problems 
attending school
1/19 (5.3%) 1/15 (6.7%) 1/19 (5.3%) 1/2 (50%) 0 (0%) 1/9 (11.1%) 0 (0%) 5/68 (7.4%) 2/95 (2.1%)
Satisfied with dis-
ease outcome
13 (59.1%) 23 (88.5%) 18 (72%) 3 (60%) 4 (100%) 7 (53.8%) 4 (80%) 72 (72%)
S271Rheumatology International (2018) 38 (Suppl 1):S267–S274 
1 3
Equal item‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 5 and 15, and for 80% 
of the HRQoL items, with the exception of items 1, 5 and 9.
Items internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 60% of items 
of the PF (except for PF items 5, 11, 12, 13, 14, and 15) and 
90% of items of the HRQoL (except for HRQoL item 9).
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/200 Child N = 82/180
Missing values (first–third quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 88.0% 91.5%
 HRQoL PhH 69.0% 70.7%
 HRQoL PsH 67.0% 73.2%
 Pain VAS 50.0% 40.2%
 Disease activity VAS 51.0% 46.3%
 Well-being VAS 51.0% 43.9%
Ceiling effect, median
 PF 0.0% 1.2%
 HRQoL PhH 2.0% 2.4%
 HRQoL PsH 1.0% 1.2%
 Pain VAS 2.0% 3.7%
 Disease activity VAS 3.0% 4.9%
 Well-being VAS 6.0% 8.5%
Items with equivalent item-scale correlation 87% for PF, 80% for HRQoL 80% for PF, 100% for HRQoL
Items with item-scale correlation ≥ 0.4 60% for PF, 90% for HRQoL 53% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.77 0.71
 PF-HW 0.83 0.78
 PF-US 0.43 0.33
 HRQoL PhH 0.82 0.87
 HRQoL PsH 0.76 0.83
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.96 0.76
 HRQoL PhH 0.98 0.00
 HRQoL PsH 0.91 0.85
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.6
 HRQoL PhH 0.4 0.5
 HRQoL PsH 0.3 0.2
 Pain VAS 0.4 0.4
 Disease activity VAS 0.1 0.2
 Well-being VAS 0.4 0.4
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.77 for PF-LL, 0.83 for PF-HW, and 
0.43 for PF-US. Cronbach’s alpha was 0.82 for HRQoL PhH 
and 0.76 for HRQoL PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 7 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 7 days (7–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.96). The ICC for the HRQoL PhH 
and for the HRQoL PsH scores showed an almost perfect 
reproducibility (ICC = 0.98 and ICC = 0.91, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent’s assessment of pain (r = 0.6, p < 
0.001). The correlation of the PF total score with the ESR 
was not significant (p = 0.61). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.4 to 0.5 (median = 0.4), whereas that 
for the PsH ranged from 0.3 to 0.4 (median = 0.3). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.6, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.4, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centered and 
laboratory measures were 0.4 (0.2–0.5), 0.1 (− 0.1–0.2), and 
0.4 (0.2–0.5), respectively.
Discussion
In this study, the Libyan Arabic version of the JAMAR is 
the result of the local adaptation of the translation in Arabic 
performed by the PRINTO centre in Saudi Arabia. Accord-
ing to the results of the validation analysis, the Libyan 
Arabic parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. Notably, there was 
no significant difference between the healthy subjects and 
their affected peers in the school-related problems variable. 
This finding indicates that children with JIA adapt well to 
the consequences of JIA. The PF total score revealed to be 
able to discriminate between the different JIA subtypes with 
the children diagnosed with RF+ polyarthritis and psoriatic 
arthritis having a higher degree of disability.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: 6 PF items (“bend 
down to pick up an object off the floor”, “stretch out arms”, 
“put hands behind neck”, “turn head and look over shoul-
ders”, “bend head back and look at the ceiling”, and “bite a 
sandwich or an apple”) and 1 HRQoL item (“have difficulty 
concentrating or paying attention”) showed a lower items 
internal consistency. However, the overall internal consist-
ency was acceptable for all the domains (with the exception 
of Cronbach’s alpha for PF-US that was < 0.5).
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from very weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Libyan Arabic version of the JAMAR 
was found to have satisfactory psychometric properties, and 
it is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
Acknowledgements We thank all families who participated in the pro-
ject, the team that prepared and reviewed the forward and backward 
translations, and all members of PRINTO in Libya. We thank the staff 
of the PRINTO International Coordinating Centre in Genoa (Italy) 
and in particular Marco Garrone for the overall coordination of the 
translation process, Silvia Scala and Elisa Patrone for data collection 
and quality assurance, Luca Villa, Giuseppe Silvestri and Mariangela 
Rinaldi for the database development and management, and the remain-
ing PRINTO team for data entry. The Principal Investigator of the 
study was Prof. Angelo Ravelli, MD. The scientific coordinator and 
study methodologist was Nicolino Ruperto, MD, MPH. The project 
coordinators were Alessandro Consolaro, MD, PhD, Francesca Bovis, 
BsA. We thank also Prof. Alberto Martini, PRINTO Chairman. Fund-
ing were provided by the Istituto G. Gaslini, Genoa (Italy). Permission 
for use of JAMAR and its translations must be obtained in writing 
from PRINTO, Genoa, Italy. All JAMAR-related inquiries should be 
directed to at printo@gaslini.org. Permission for use of CHAQ and 
CHQ derived-material is granted through the scientific cooperation of 
the copyright holder ICORE of Woodside CA and HealthActCHQ Inc. 
of Boston, Massachusetts, USA. All CHQ-related inquiries should be 
directed to licensing@healthactchq.com. All CHAQ-related inquiries 
should be directed to gsingh@stanford.edu.
S273Rheumatology International (2018) 38 (Suppl 1):S267–S274 
1 3
Funding This study was funded and coordinated by Istituto Giannina 
Gaslini, Genoa, Italy.
Compliance with ethical standards 
Conflict of interest Dr. Al-Mayouf reports funding support from Isti-
tuto Giannina Gaslini, Genoa, Italy, for the data collection performed 
at his site within the EPOCA project. Dr. Ruperto has received grants 
from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi, during 
the conduct of the study and personal fees and speaker honorarium 
from Abbvie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Bio-
gen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD 
Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rp-
harm, Roche, Sanofi, Servier, and Takeda. Dr. Consolaro, Dr. Bovis, 
Dr. Etayari, Dr. Etfil, Dr. Hashad, Dr. Ibrahim, and Dr. Zletni have 
nothing to disclose.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants included in the study as per the requirement of the local 
ethical committee.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi 
B, Magni-Manzoni S et al (2011) A new approach to clinical care 
of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimen-
sional Assessment Report. J Rheumatol 38(5):938–953
 2. Ruperto N, Martini A (2011) Networking in paediatrics: the exam-
ple of the Paediatric Rheumatology International Trials Organisa-
tion (PRINTO). Arch Dis Child 96(6):596–601
 3. Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, 
Garrone M et al (2012) Seeking insights into the epidemiology, 
treatment and outcome of childhood arthritis through a multi-
national collaborative effort: introduction of the EPOCA study. 
Pediatr Rheumatol Online J 10(1):39
 4. Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone 
E et al (2018) Cross-cultural adaptation and psychometric evalu-
ation of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) in 54 languages across 52 countries: review of 
the general methodology. Rheumatol Int. https ://doi.org/10.1007/
s0029 6-018-3944-1 (in this issue)
 5. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Man-
ners P et al (1998) Revision of the proposed classification crite-
ria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 
25(10):1991–1994
 6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Gold-
enberg J et al (2004) International League of Associations for 
Rheumatology classification of juvenile idiopathic arthritis: sec-
ond revision, Edmonton, 2001. J Rheumatol 31(2):390–392
 7. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, 
Pistorio A, Viola S et al (2007) Development and validation of a 
new short and simple measure of physical function for juvenile 
idiopathic arthritis. Arthritis Rheum 57(6):913–920
 8. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M et al 
(1989) Development of a disability measurement tool for juvenile 
rheumatoid arthritis. The juvenile arthritis functional assessment 
scale. Arthritis Rheum 32:1390–1395
 9. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M 
et al (1991) Development of a disability measurement tool for 
juvenile rheumatoid arthritis. The juvenile arthritis functional 
assessment report for children and their parents. Arthritis Rheum 
34:873–880
 10. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measure-
ment of health status in children with juvenile rheumatoid arthri-
tis. Arthritis Rheum 37:1761–1769
 11. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lat-
tanzi B et al (2010) Evaluation of 21-numbered circle and 10-cen-
timeter horizontal line visual analog scales for physician and par-
ent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 
37(7):1534–1541
 12. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczyn-
ski H (1997) The Juvenile Arthritis Quality of Life Question-
naire–development of a new responsive index for juvenile rheu-
matoid arthritis and juvenile spondyloarthritides. J Rheumatol 
24(4):738–746
 13. Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS 
(2002) The PedsQL(TM) in pediatric rheumatology—reliabil-
ity, validity, and responsiveness of the pediatric quality of life 
inventory(TM) generic core scales and rheumatology module. 
Arthritis Rheum 46(3):714–725
 14. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual. 
First Edn. The Health Institute, New England Medical Center, 
Boston
 15. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio 
A, Solari N et al (2012) Parent and child acceptable symptom state 
in juvenile idiopathic arthritis. J Rheumatol 39(4):856–863
 16. Nunnally JC (1978) Psychometric theory, 2nd edn. McGraw-Hill, 
New York
 17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Mar-
tini A (1997) Preliminary definition of improvement in juvenile 
arthritis. Arthritis Rheum 40(7):1202–1209
 18. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) 
MAP-R for windows: multitrait/multi-item analysis program—
revised user’s guide. Version 1.0 ed. Health Assessment Lab, 
Boston
S274 Rheumatology International (2018) 38 (Suppl 1):S267–S274
1 3
Affiliations
Soad Hashad1 · Mabruka Ahmed Zletni1 · Sulaiman M. Al‑Mayouf2 · Hala Etayari1 · Eman Ibrahim1 · Majeda Etfil1 · 
Alessandro Consolaro3,4 · Francesca Bovis3 · Nicolino Ruperto3 · For the Paediatric Rheumatology International 
Trials Organisation (PRINTO)
 Mabruka Ahmed Zletni 
 dr_zletni@hotmail.com
 Sulaiman M. Al-Mayouf 
 mayouf@kfshrc.edu.sa
 Hala Etayari 
 halaetayari@hotmail.com
 Eman Ibrahim 
 eimanibrahim@hotmail.com
 Majeda Etfil 
 Mag81da@yahoow.com
 Alessandro Consolaro 
 alessandroconsolaro@gaslini.org
 Francesca Bovis 
 francescabovis@gaslini.org
1 Tripoli Children’s Hospital, Omar Almukthar Street, Tripoli, 
Libya
2 Department of Pediatric Rheumatology, King Faisal 
Specialist Hospital and Research Center, Alfaisal University, 
Riyadh, Saudi Arabia
3 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology 
International Trials Organisation (PRINTO), Istituto 
Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
4 Dipartimento di Pediatria, Università di Genova, Genoa, Italy
